Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals

PLoS Genetics

Volumn 3, Issue 1, 2007, Pages 0123-0132

  An, Ping ^a   Duggal, Priya ^b   Li, Hua Wang ^a   O'Brien, Stephen J ^c   Donfield, Sharyne ^d   Goedert, James J ^e   Phair, John ^f   Buchbinder, Susan ^g   Kirk, Gregory D ^h   Winkler, Cheryl A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d RHO INC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CULLIN; CULLIN 5; UNCLASSIFIED DRUG; CUL5 PROTEIN, HUMAN; PRIMER DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; GENE LOCUS; GENE MAPPING; GENETIC POLYMORPHISM; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; AFRICAN AMERICAN; COHORT ANALYSIS; CYTOLOGY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; IMMUNOLOGY; LONGITUDINAL STUDY; MULTIGENE FAMILY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AFRICAN AMERICANS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CULLIN PROTEINS; DNA PRIMERS; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; LINKAGE DISEQUILIBRIUM; LONGITUDINAL STUDIES; LYMPHOCYTE DEPLETION; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33846484745     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.0030019     Document Type: Article

References (47)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
2. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073-6076.
3. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
4. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
5. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
7. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
8. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, et al. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 279: 7792-7798.
9. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 13: 2009-2013.
10. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398-1403.
11. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
12. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12: 591-601.
13. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, et al. (2004) Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1: 27.
14. Liu B, Sarkis PTN, Luo K, Yu Y, Yu X-F (2005) Regulation of Apobec3F and Human Immunodeficiency Virus Type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79: 9579-9587.
15. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, et al. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A 102: 11444-11449.
16. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, et al. (2006) Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349: 290-299.
17. Mehle A, Thomas ER, Rajendran KS, Gabuzda D (2006) A Zinc-binding region in Vif binds Cul5 and determines Cullin selection. J Biol Chem 281: 17259-17265.
18. An P, Bleiber G, Duggal P, Nelson G, May M, et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 78: 11070-11076.
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229.
20. Bandelt HJ, Forster P, Sykes BC, Richards MB (1995) Mitochondrial portraits of human populations using median networks. Genetics 141: 743-753.
21. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T (2005) Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex Is essential for Vif function. J Biol Chem 280: 18573-18578.
22. Byrd PJ, Stankovic T, McConville CM, Smith AD, Cooper PR, et al. (1997) Identification and analysis of expression of human VACM-1, a cullin gene family member located on chromosome 11q22-23. Genome Res 7: 71-75.
23. Burnatowska-Hledin M, Zhao P, Capps B, Poel A, Parmelee K, et al. (2000) VACM-1, a cullin gene family member, regulates cellular signaling. Am J Physiol Cell Physiol 279: C266-C273.
24. + cell count. JAMA 279: 35-40.
25. Phair J, Jacobson L, Detels R, Rinaldo C, Saah A, et al. (1992) Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 5: 490-496.
26. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD (1994) Long-term HIV-1 infection without immunologic progression. Aids 8: 1123-1128.
27. Hilgartner MW, Donfield SM, Willoughby A, Contant CF Jr., Evatt BL, et al. (1993) Hemophilia growth and development study. Design, methods, and entry data. Am J Pediatr Hematol Oncol 15: 208-218.
28. Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, et al. (1989) A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 321: 1141-1148.
29. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, et al. (2001) Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. Aids 15: 1707-1715.
30. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41: 1-19.
31. Centers for Disease Control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR 36 Suppl 1: 1S-15S.
32. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
33. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. (1997) Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277: 959-965.
34. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, et al. (1998) Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282: 1907-1911.
35. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, et al. (2005) AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 11: 1290-1292.
36. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 344: 1668-1675.
37. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, et al. (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2: 405-411.
38. O'Brien SJ, Nelson GW, Winkler CA, Smith MW (2000) Polygenic and multifactorial disease gene association in man: Lessons from AIDS. Annu Rev Genet 34: 563-591.
39. Akaike H (1973) Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csake E, editors. 2nd International Symposium on Information Theory. Akademiai Kiado: Budapest. pp. 267-281.
40. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
41. Yang Q, Cui J, Chazaro I, Cupples LA, Demissie S (2005) Power and type I error rate of false discovery rate approaches in genome-wide association studies. BMC Genet 6 Suppl 1: S134.
42. Freimer NB, Sabatti C (2005) Guidelines for association studies in human molecular genetics. Hum Mol Genet 14: 2481-2483.
43. Lewontin RC (1964) The interaction of selection and linkage. II. Optimum models. Genetics 50: 757-782.
44. Barrett JC, Fry B, Maller J, Daly MJ (2004) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
45. Long JC, Williams RC, Urbanek M (1995) An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 56: 799-810.
46. Wang LH, Kirken RA, Erwin RA, Yu C-R, Farrar WL (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 162: 3897-3904.
47. Wang LH, Yang XY, Kirken RA, Resau JH, Farrar WL (2000) Targeted disruption of Stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven TH2 cell response. Blood 95: 1249-1257.